A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Novartis
- 18 Oct 2017 Hiroshi Handa, M.D. is a lead investigator from Maebashi-city, Gunma, Japan.
- 13 Oct 2017 Planned End Date changed from 3 Jan 2019 to 8 Jul 2019.
- 13 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 30 Jan 2018.